 Connection
David Moreno to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications David Moreno has written about Antineoplastic Combined Chemotherapy Protocols.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.611 |
|
|
|
-
Moreno DF, Oriol A, de la Rubia J, Hernández MT, Iñigo MB, Palomera L, de Arriba F, González Y, Teruel AI, Pardo JL, López de la Guía A, Sampol A, Ríos-Tamayo R, Sureda A, Gutiérrez NC, Calasanz MJ, Ramos MLM, Mateos MV, San Miguel J, Lahuerta JJ, Bladé J, Rosiñol L. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):494-504.
Score: 0.481
-
Moreno DF, Clapés V, Soler JA, González-Montes Y, Gironella M, Motlló C, Granell M, Abella E, García-Pintos M, García-Guiñón A, Cabezudo E, Bladé J, Rosiñol L. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):635-642.
Score: 0.099
-
Durot E, Abeykoon JP, Roos-Weil D, Kersten MJ, Kyriakou C, Moreno DF, Ansell SM, Auer R, Cao X, Owen RG, Yi S, Dogliotti I, Trneny M, Patterson CJ, Matous JV, Buske C, Treon SP, Advani R. Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia. Semin Hematol. 2025 Apr; 62(2):120-125.
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|